AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11887516 — intervention group
Group type: EXPERIMENTAL
Intervention: BrushPicks
Number of subjects: 63
Study 11887516 — intervention group
Group type: COMPARATOR
Intervention: Glide floss
Number of subjects: 63
Study 9728982 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stent implantation
Number of subjects: 827
Study 9728982 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 827
Study 8034762 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral family systems therapy (BFST)
Number of subjects: 22
Study 8034762 — intervention group
Group type: COMPARATOR
Intervention: Ego-oriented individual therapy (EOIT)
Number of subjects: 22
Study 3276642 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative shampoos with chlorhexidine
Number of subjects: 151
Study 3276642 — intervention group
Group type: COMPARATOR
Intervention: No shampoos, surgical preparation with chlorhexidine
Number of subjects: 151
Study 3276642 — intervention group
Group type: COMPARATOR
Intervention: Shampoos with iodophor, surgical preparation with iodophor
Number of subjects: 151
Study 3276642 — intervention group
Group type: COMPARATOR
Intervention: No shampoos, surgical preparation with iodophor
Number of subjects: 151
Study 1137332 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose solution infusion (glucose group)
Number of subjects: 60
Study 1137332 — intervention group
Group type: COMPARATOR
Intervention: 0.9% physiological saline solution infusion (saline group)
Number of subjects: 60
Study 31308263 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided transmuscular quadratus lumborum block with 30 mL ropivacaine 0.375%
Number of subjects: 72
Study 31308263 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 72
Study 29097935 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized contrast medium injection protocol (G1)
Number of subjects: 324
Study 29097935 — intervention group
Group type: COMPARATOR
Intervention: Standard contrast medium injection (G2) with a dose of 1.5 ml/kg
Number of subjects: 324
Study 29097935 — intervention group
Group type: COMPARATOR
Intervention: Standard contrast medium injection (G2)
Number of subjects: 324
Study 29097935 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups evaluated by two independent radiologists
Number of subjects: 324
Study 26303805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual artemether (3 mg/kg body weight)
Number of subjects: 182
Study 26303805 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine (loading dose of 20 mg/kg followed by 10 mg/kg every 8 h)
Number of subjects: 182
Study 26303805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual artemether
Number of subjects: 182
Study 26303805 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 182
Study 24604111 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A (BtX‐A) injection (200 IU) in the calf muscle of one leg
Number of subjects: 36
Study 24604111 — intervention group
Group type: COMPARATOR
Intervention: Sterile normal saline injection in the other leg (control)
Number of subjects: 36
Study 22459346 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Urethral Mobility Examination (VUME)
Number of subjects: 54
Study 22459346 — intervention group
Group type: COMPARATOR
Intervention: Q-Tip test
Number of subjects: 54
Study 19173737 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 3957
Study 19173737 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 3957
Study 19173737 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab + IFN-a
Number of subjects: 3957
Study 19173737 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 3957
Study 17588224 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking pictures
Number of subjects: 22
Study 17588224 — intervention group
Group type: COMPARATOR
Intervention: Unpleasant pictures
Number of subjects: 22
Study 17588224 — intervention group
Group type: COMPARATOR
Intervention: Pleasant pictures
Number of subjects: 22
Study 15364166 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4 mg
Number of subjects: 127
Study 15364166 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 127
Study 15364166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 15364166 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 2 mg
Number of subjects: 127
Study 11584152 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium 500 mg three times per day for 7 days
Number of subjects: 36
Study 11584152 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 36
Study 9559475 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-surface-modified (HSM) intraocular lenses (IOLs)
Number of subjects: 100
Study 9559475 — intervention group
Group type: COMPARATOR
Intervention: Unmodified poly(methyl methacrylate) (PMMA) intraocular lenses (IOLs)
Number of subjects: 100
Study 8162671 — intervention group
Group type: EXPERIMENTAL
Intervention: AA-2414
Number of subjects: 39
Study 3064527 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive plasmapheresis (plasma exchanges every 2 to 3 days during a period of 2 to 3 weeks) with continuation of oral immunosuppressive therapy
Number of subjects: 0
Study 3064527 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic intermittent treatment (once per week) with parallel immunosuppression
Number of subjects: 0
Study 3064527 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 plasmaphereses followed by an i.v. cyclophosphamide bolus
Number of subjects: 0
Study 1703611 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP (0.1 mg i.v. as a bolus)
Number of subjects: 6
Study 1703611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 124394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment and tulle dressing with 1500 mg Complain in 500 ml physiological saline solution daily for three days postoperatively
Number of subjects: 95
Study 124394 — intervention group
Group type: COMPARATOR
Intervention: Perforated cellophane dressing without additional medication
Number of subjects: 95
Study 30668833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate catheter lock solution (SBCLS)
Number of subjects: 451
Study 30668833 — intervention group
Group type: COMPARATOR
Intervention: Normal saline catheter lock solution (NSCLS)
Number of subjects: 451
Study 28389109 — intervention group
Group type: COMPARATOR
Intervention: TBI group
Number of subjects: 153
Study 26368824 — intervention group
Group type: EXPERIMENTAL
Intervention: MRK Ad5 gag/pol/nef subtype B HIV‐1 preventive vaccine
Number of subjects: 465
Study 26368824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study 24140372 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated foldable intraocular lens (Polylens EC‐1YH PAL)
Number of subjects: 40
Study 24140372 — intervention group
Group type: COMPARATOR
Intervention: Control intraocular lens (Polylens EC‐1Y PAL)
Number of subjects: 40
Study 22028418 — intervention group
Group type: EXPERIMENTAL
Intervention: VA‐MEDIC‐D (pharmacist-led group SMA visits)
Number of subjects: 44
Study 22028418 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 44
Study 22028418 — intervention group
Group type: EXPERIMENTAL
Intervention: VA‐MEDIC‐D
Number of subjects: 44
Study 22028418 — intervention group
Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 44
Study 19722800 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan gel administered subgingivally
Number of subjects: 12
Study 19722800 — intervention group
Group type: COMPARATOR
Intervention: Control group (scaling and root planing only)
Number of subjects: 12
Study 17369119 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 131
Study 17369119 — intervention group
Group type: COMPARATOR
Intervention: 2 mg apomorphine
Number of subjects: 131
Study 16013897 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 197
Study 11133595 — intervention group
Group type: EXPERIMENTAL
Intervention: AIIA given 1 h before anesthesia (n = 19)
Number of subjects: 37
Study 11133595 — intervention group
Group type: COMPARATOR
Intervention: AIIA discontinued on the day before surgery (n = 18)
Number of subjects: 37
Study 9753234 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg daily for eight weeks (group O)
Number of subjects: 60
Study 9753234 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for eight weeks + Rebamipide 300 mg three times a day for eight weeks (group OR)
Number of subjects: 60
Study 9753234 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for eight weeks + Amoxicillin 1500 mg three times a day for the first two weeks (group OA)
Number of subjects: 60
Study 7992465 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex (50 mg daily)
Number of subjects: 34
Study 7992465 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy (control)
Number of subjects: 34
Study 3416419 — intervention group
Group type: EXPERIMENTAL
Intervention: Allerglobuline (10% human immunoglobulin preparation of placental origin)
Number of subjects: 80
Study 3416419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10% human albumin solution)
Number of subjects: 80
Study 29210705 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 20
Study 29210705 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection (control)
Number of subjects: 20
Study 28202842 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g/d of trehalose
Number of subjects: 34
Study 28202842 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 34
Study 24861098 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity (MPA)
Number of subjects: 63
Study 24861098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 63
Study 22192104 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally tubeless PCNL (Group A)
Number of subjects: 23
Study 22192104 — intervention group
Group type: COMPARATOR
Intervention: Standard PCNL (Group B)
Number of subjects: 23
Study 22192104 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study 20387996 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg EPs 7630 tablets three times a day (30‐mg group)
Number of subjects: 406
Study 20387996 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg EPs 7630 tablets three times a day (60‐mg group)
Number of subjects: 406
Study 20387996 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg EPs 7630 tablets three times a day (90‐mg group)
Number of subjects: 406
Study 20387996 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times a day
Number of subjects: 406
Study 17914002 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement interventions (education and resources for medication management or psychotherapy) for 6 to 12 months
Number of subjects: 1248
Study 17914002 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1248
Study 16193893 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR peptides/IFA
Number of subjects: 24
Study 16193893 — intervention group
Group type: COMPARATOR
Intervention: TCR peptides/saline
Number of subjects: 24
Study 16193893 — intervention group
Group type: COMPARATOR
Intervention: IFA alone
Number of subjects: 24
Study 12658557 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2 h before and placebo 1 h before Nd : YAG laser capsulotomy
Number of subjects: 217
Study 12658557 — intervention group
Group type: COMPARATOR
Intervention: Apraclonidine 1 h before the procedure and placebo 2 h before
Number of subjects: 217
Study 10474124 — intervention group
Group type: COMPARATOR
Intervention: Lanreotide-SR (LSR) administered at individually tailored dosages (30 mg i.m. at 7-21-day intervals)
Number of subjects: 12
Study 10474124 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR (OC-LAR) administered at 20 mg for the first three doses and 10 or 30 mg for the last three doses at 28-day intervals
Number of subjects: 12
Study 10474124 — intervention group
Group type: COMPARATOR
Intervention: Lanreotide-SR (LSR)
Number of subjects: 12
Study 10474124 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR (OC-LAR)
Number of subjects: 12
Study 8556398 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) 500 mg daily
Number of subjects: 467
Study 8556398 — intervention group
Group type: COMPARATOR
Intervention: Zalcitabine (ddC) 2.25 mg daily
Number of subjects: 467
Study 1806376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg b.i.d.
Number of subjects: 489
Study 1806376 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 489
Study 6614421 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 12
Study 6614421 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 12
Study 31759097 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 91
Study 31759097 — intervention group
Group type: COMPARATOR
Intervention: Bronchial washing (BW)
Number of subjects: 91
Study 31759097 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL
Number of subjects: 91
Study 31759097 — intervention group
Group type: COMPARATOR
Intervention: BW
Number of subjects: 91
Study 29514235 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced antimicrobial prophylaxis
Number of subjects: 1711
Study 29514235 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (n = 355)
Number of subjects: 1711
Study 29514235 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (n = 394)
Number of subjects: 1711
Study 29514235 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (n = 218)
Number of subjects: 1711
Study 29514235 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaining groups
Number of subjects: 1711
Study 27435979 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2940094 (40 mg/d)
Number of subjects: 88
Study 27435979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 24216403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (1.5‐mg/kg bolus followed by 2‐mg/kg/h infusion)
Number of subjects: 51
Study 24216403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion
Number of subjects: 51
Study 24216403 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (placebo)
Number of subjects: 51
Study 22252909 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (up to 225 mg/day)
Number of subjects: 41
Study 22252909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 20497980 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in sugar-sweetened beverage (SSB) intake by 1 serving per day
Number of subjects: 810
Study 20497980 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in sugar intake
Number of subjects: 810
Study 20497980 — intervention group
Group type: COMPARATOR
Intervention: Diet beverage consumption
Number of subjects: 810
Study 20497980 — intervention group
Group type: COMPARATOR
Intervention: Caffeine intake
Number of subjects: 810
Study 17442601 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 129
Study 16275676 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential administration of paclitaxel followed by oral fluoropyrimidines (UFT/S1)
Number of subjects: 1480
Study 16275676 — intervention group
Group type: COMPARATOR
Intervention: UFT/S1
Number of subjects: 1480
Study 16275676 — intervention group
Group type: COMPARATOR
Intervention: S1
Number of subjects: 1480
Study 12085075 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye patch
Number of subjects: 37
Study 12085075 — intervention group
Group type: COMPARATOR
Intervention: No eye patch
Number of subjects: 37
Study 10451462 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR
Number of subjects: 750
Study 10451462 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 750
Study 8678249 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (starting with 9 mg.kg‐1 h‐1, reducing to 6 mg.kg‐1 h‐1 after 20 min)
Number of subjects: 60
Study 8678249 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5% end‐tidal)
Number of subjects: 60
Study 8678249 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60
Study 8678249 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 8678249 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.15 mg.kg‐1
Number of subjects: 60
Study 1691357 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (40 mg once daily)
Number of subjects: 15
Study 1691357 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg twice daily)
Number of subjects: 15
Study 1691357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 398483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (250 mg every 8 hours for 7 to 10 days)
Number of subjects: 61
Study 398483 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (250 mg every 8 hours for 7 to 10 days)
Number of subjects: 61
Study 398483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 61
Study 398483 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor and Amoxycillin
Number of subjects: 61
Study 31782656 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help (low-intensity cognitive behaviour therapy including behavioural activation)
Number of subjects: 70
Study 31782656 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 70
Study 31139365 — intervention group
Group type: EXPERIMENTAL
Intervention: Edutainment video
Number of subjects: 363
Study 31139365 — intervention group
Group type: COMPARATOR
Intervention: Standard Operating Procedure (SOP)
Number of subjects: 363
Study 31139365 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 363
Study 31139365 — intervention group
Group type: COMPARATOR
Intervention: SOP
Number of subjects: 363
Study 28640136 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE)
Number of subjects: 216
Study 28640136 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise with a behavioral approach (NSEB)
Number of subjects: 216
Study 28640136 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription of physical activity (PPA)
Number of subjects: 216
Study 25542740 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised (plain) cigarette packaging
Number of subjects: 30
Study 25542740 — intervention group
Group type: COMPARATOR
Intervention: Manufacturer-designed (branded) cigarette packaging
Number of subjects: 30
Study 23992003 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration (FNA)
Number of subjects: 100
Study 21825283 — intervention group
Group type: EXPERIMENTAL
Intervention: supervised moderate‐intensity physical activity program
Number of subjects: 1600
Study 21825283 — intervention group
Group type: COMPARATOR
Intervention: successful aging health education program
Number of subjects: 1600
Study 19664253 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (1.3 microg.kg‐1.h‐1)
Number of subjects: 45
Study 19664253 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin (.03 U.min‐1)
Number of subjects: 45
Study 19664253 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (15 microg.min‐1)
Number of subjects: 45
Study 17209185 — intervention group
Group type: COMPARATOR
Intervention: Physical activity level (PAL) of 1.4
Number of subjects: 10
Study 17209185 — intervention group
Group type: COMPARATOR
Intervention: Physical activity level (PAL) of 1.6
Number of subjects: 10
Study 17209185 — intervention group
Group type: COMPARATOR
Intervention: Physical activity level (PAL) of 1.8
Number of subjects: 10
Study 15140756 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone replacement (GHR)
Number of subjects: 0
Study 15140756 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH‐(1‐34) infusion
Number of subjects: 0
Study 15140756 — intervention group
Group type: EXPERIMENTAL
Intervention: GHR
Number of subjects: 0
Study 11236299 — intervention group
Group type: EXPERIMENTAL
Intervention: Becotide (innovator formulation)
Number of subjects: 36
Study 11236299 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclate (generic formulation)
Number of subjects: 36
Study 9504622 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction instrument used in 24 ears
Number of subjects: 27
Study 9504622 — intervention group
Group type: COMPARATOR
Intervention: No suction instrument used in 27 ears
Number of subjects: 27
Study 9094727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 20
Study 9094727 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 20
Study 2031258 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg daily for 14 days
Number of subjects: 16
Study 2031258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6294175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 59
Study 6294175 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 1 g daily
Number of subjects: 59
Study 6294175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily (open treatment)
Number of subjects: 59
Study 30523522 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate (PP1M) (50-150 mg equivalent)
Number of subjects: 72
Study 30523522 — intervention group
Group type: COMPARATOR
Intervention: Oral Paliperidone Extended Release (ER) (6-12 mg/day)
Number of subjects: 72
Study 28197844 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS + SoC
Number of subjects: 97
Study 25277322 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid lipid curcumin (400 mg as Longvida)
Number of subjects: 60
Study 25277322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60